2/13/2007 Study Shows Liver an Excellent Target For Cancer Gene Therapy Using Viral Vectors A featured paper in the February issue of the research journal Cancer Gene Therapy demonstrates that cancer cells in the liver are excellent targets for gene therapy
using adenoviral vectors, based upon a fundamental new understanding of the differen... More...
A featured paper in the February issue of the research journal Cancer Gene Therapy demonstrates that cancer cells in the liver are excellent targets for gene therapy
using adenoviral vectors, based upon a fundamental new understanding of the differences between cancerous and normal liver cells.
In the current work
we used adenoviral - type 5 (dE1 / E3)(Cytomegalovirus promoter) with human ABCA10 transgene (Ad - h - ABCA10) purchased from Vector Labs ® in order to investigate whether gene therapy can be used as a pre-treatment to enhance the efficiency of inhaled cisplatin.
Not exact matches
In PNP's Phase I trial, an
adenoviral vector is
used to deliver E. coli PNP to head and neck tumors followed by intravenous administration of the prodrug fludarabine.
Additionally, the
adenoviral generation of the iPSCs did not lead to any teratomas or other abnormalities suggesting that they are safe for this type of
use.
Lack of preexisting virus - neutralizing antibodies in the human population suggests that these novel
adenoviral recombinants may provide improved vaccine carriers for
use in humans.
The gene - targeting approach developed by Suzuki and his colleagues relies on the
use of so - called helper - dependent
adenoviral vector to deliver large mutation - free DNA molecules into cells.
«At that time, I was treating patients with colon cancer that had spread to the liver
using a very similar
adenoviral vector administered in exactly the same way — direct infusion into the main artery feeding the liver,» said Reid, who is now an associate professor of clinical medicine in the UCSD School of Medicine.
The disorganized structure of the cancer cells exposes the receptors so that Onyx - 015, the
adenoviral vectors
used in this study, can readily enter tumor cells.
Despite the marginal improvements in survival of patients suffering from malignant glioma treated with gene therapy vectors, the clinical trials conducted so far
using viral vectors, in particular
adenoviral vectors, have proven that the
use of
adenoviral vectors is a safe therapeutic approach, even in large, multicenter, phase 3 clinical trials.
Adenoviral vectors can be produced by human embryonic kidney (HEK293) and human embryonic retinal (PER.C6) cell lines (31), both of which also can be
used for lentiviral vector production.